# Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer

> **NCT01676818** · PHASE2 · COMPLETED · sponsor: **University of Southern California** · enrollment: 32 (actual)

## Conditions studied

- Recurrent Cervical Cancer
- Stage IIIA Cervical Cancer
- Stage IIIB Cervical Cancer
- Stage IVA Cervical Cancer
- Stage IVB Cervical Cancer

## Interventions

- **DRUG:** eribulin mesylate

## Key facts

- **NCT ID:** NCT01676818
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-09
- **Primary completion:** 2021-02-21
- **Final completion:** 2021-12-22
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01676818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01676818, "Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01676818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*